Primary information |
---|
ID | 13477 |
Uniprot ID | P0C7P6 |
Description | Bradykinin-potentiating and C-type natriuretic peptides (BPP-CNP) [Cleaved into- Bradykinin-potentiating peptide Tg1 (BPP); C-type natriuretic peptide (CNP)] |
Organism | Trimeresurus gramineus |
Txonomy | Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata (jawed vertebrates); Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Sauropsida; Sauria (diapsids); Lepidosauria (lepidosaurs); Squamata (squamates); Bifurcata (split-tongued squamates); Unidentata; Episquamata; Toxicofera; Serpentes (snakes); Colubroidea; Viperidae; Crotalinae (pit vipers); Trimeresurus; Trimeresurus gramineus (Bamboo pit viper) |
Subcellular Location | Secreted |
Developmental Stage | NA |
Similarity | In the N-terminal section; belongs to the bradykinin-potentiating peptide family. |
Tissue Specificity | Expressed by the venom gland. |
Post Translational Modification | NA |
Function | Bradykinin-potentiating peptide both inhibits the activity of the angiotensin-converting enzyme (ACE) and enhances the action of bradykinin by inhibiting the peptidases that inactivate it. It acts as an indirect hypotensive agent. Tg1 does not show bradykinin-potentiating effects. |
Length | 210 |
Molecular Weight | 21 |
Name | NA |
Sequence | NA |
Sequence map | NA |
PDB ID | NA |
Drugpedia | NA |
Receptor | NA |
Domain | NA |
Pharmaceutical Use | NA
|